Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178115401> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3178115401 endingPage "1039" @default.
- W3178115401 startingPage "1034" @default.
- W3178115401 abstract "Purpose This study aimed to reveal the relationship between the level of galectin-3 expression and the depth of response to neoadjuvant therapy in bladder tumor tissue with muscle invasion revealed by transurethral biopsy. Methods The percentage of galectin-3 staining in transurethral biopsy tissue with muscle invasion was determined by immunohistochemistry. The patients were divided into two groups: the down-staging (+) group consisting of patients with pathological complete response or non-invasive bladder cancer, and the down-staging (-) group consisting of patients with stage 2 and above. Results There were 11 patients in the down-staging (+) group and 12 patients in the down-staging (-) group. There was no significant difference between the two groups in terms of median age, gender, smoking, clinical stage at the time of diagnosis, distribution of carboplatin or cisplatin used as a platinum agent. Galectin-3 was positive in 2 patients (18.2%) in the group where down-staging was achieved with neoadjuvant therapy, while it was positive in 9 patients (75%) in the other group (p = 0.01). The median follow-up period of the patients was 31.6 months (95% CI 25.1-39.3). Overall survival was 43.4 months in the down-staging (+) group (95% CI 25.1-61.6) and 31.6 months in the down-staging (-) group (95% CI 12.7-50.6). Although there was a numerical difference, it did not reach statistical significance (p=0.37). Conclusion The rate of down-staging after platinum-based neoadjuvant chemotherapy is significantly higher in patients with low galectin-3 staining in transurethral bladder biopsy tissue." @default.
- W3178115401 created "2021-07-19" @default.
- W3178115401 creator A5012019330 @default.
- W3178115401 creator A5019668026 @default.
- W3178115401 creator A5050143031 @default.
- W3178115401 creator A5056098799 @default.
- W3178115401 creator A5059941445 @default.
- W3178115401 creator A5063630319 @default.
- W3178115401 creator A5080474753 @default.
- W3178115401 creator A5081007783 @default.
- W3178115401 creator A5081694029 @default.
- W3178115401 date "2021-05-01" @default.
- W3178115401 modified "2023-09-27" @default.
- W3178115401 title "The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment." @default.
- W3178115401 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34268970" @default.
- W3178115401 hasPublicationYear "2021" @default.
- W3178115401 type Work @default.
- W3178115401 sameAs 3178115401 @default.
- W3178115401 citedByCount "0" @default.
- W3178115401 crossrefType "journal-article" @default.
- W3178115401 hasAuthorship W3178115401A5012019330 @default.
- W3178115401 hasAuthorship W3178115401A5019668026 @default.
- W3178115401 hasAuthorship W3178115401A5050143031 @default.
- W3178115401 hasAuthorship W3178115401A5056098799 @default.
- W3178115401 hasAuthorship W3178115401A5059941445 @default.
- W3178115401 hasAuthorship W3178115401A5063630319 @default.
- W3178115401 hasAuthorship W3178115401A5080474753 @default.
- W3178115401 hasAuthorship W3178115401A5081007783 @default.
- W3178115401 hasAuthorship W3178115401A5081694029 @default.
- W3178115401 hasConcept C121608353 @default.
- W3178115401 hasConcept C126322002 @default.
- W3178115401 hasConcept C126894567 @default.
- W3178115401 hasConcept C143998085 @default.
- W3178115401 hasConcept C146357865 @default.
- W3178115401 hasConcept C151730666 @default.
- W3178115401 hasConcept C204232928 @default.
- W3178115401 hasConcept C207886595 @default.
- W3178115401 hasConcept C2775934546 @default.
- W3178115401 hasConcept C2776694085 @default.
- W3178115401 hasConcept C2778239845 @default.
- W3178115401 hasConcept C2778292576 @default.
- W3178115401 hasConcept C2780352672 @default.
- W3178115401 hasConcept C2781451048 @default.
- W3178115401 hasConcept C2992528526 @default.
- W3178115401 hasConcept C530470458 @default.
- W3178115401 hasConcept C63363279 @default.
- W3178115401 hasConcept C65409693 @default.
- W3178115401 hasConcept C71924100 @default.
- W3178115401 hasConcept C86803240 @default.
- W3178115401 hasConcept C90924648 @default.
- W3178115401 hasConceptScore W3178115401C121608353 @default.
- W3178115401 hasConceptScore W3178115401C126322002 @default.
- W3178115401 hasConceptScore W3178115401C126894567 @default.
- W3178115401 hasConceptScore W3178115401C143998085 @default.
- W3178115401 hasConceptScore W3178115401C146357865 @default.
- W3178115401 hasConceptScore W3178115401C151730666 @default.
- W3178115401 hasConceptScore W3178115401C204232928 @default.
- W3178115401 hasConceptScore W3178115401C207886595 @default.
- W3178115401 hasConceptScore W3178115401C2775934546 @default.
- W3178115401 hasConceptScore W3178115401C2776694085 @default.
- W3178115401 hasConceptScore W3178115401C2778239845 @default.
- W3178115401 hasConceptScore W3178115401C2778292576 @default.
- W3178115401 hasConceptScore W3178115401C2780352672 @default.
- W3178115401 hasConceptScore W3178115401C2781451048 @default.
- W3178115401 hasConceptScore W3178115401C2992528526 @default.
- W3178115401 hasConceptScore W3178115401C530470458 @default.
- W3178115401 hasConceptScore W3178115401C63363279 @default.
- W3178115401 hasConceptScore W3178115401C65409693 @default.
- W3178115401 hasConceptScore W3178115401C71924100 @default.
- W3178115401 hasConceptScore W3178115401C86803240 @default.
- W3178115401 hasConceptScore W3178115401C90924648 @default.
- W3178115401 hasIssue "3" @default.
- W3178115401 hasLocation W31781154011 @default.
- W3178115401 hasOpenAccess W3178115401 @default.
- W3178115401 hasPrimaryLocation W31781154011 @default.
- W3178115401 hasVolume "26" @default.
- W3178115401 isParatext "false" @default.
- W3178115401 isRetracted "false" @default.
- W3178115401 magId "3178115401" @default.
- W3178115401 workType "article" @default.